Friday, July 10, 2026

pharma · wet macula degeneration · Chronic Urticaria

CuraTeQ Biologics s.r.o

CuraTeQ Biologics s.r.o clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Hyderabad, IN HQ
2016 Founded
645 Employees
EMA registrant Type
Company details
Status
Public
HQ
Hyderabad, IN
Founded
2016
Employees
645
Programs
2
Drugs
6
Patents
0
Intelligence · Clinical Programs

CuraTeQ Biologics s.r.o projects

2 ClinicalTrials.gov programs sponsored by CuraTeQ Biologics s.r.o.

CuraTeQ Biologics s.r.o has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. BP11-301

    CuraTeQ Biologics s.r.o

    Chronic Urticaria

    phase 3 small molecule active

    1 trial
  2. CR213-20

    CuraTeQ Biologics s.r.o

    wet macula degeneration

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does CuraTeQ Biologics s.r.o have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.